Defective blood glucose counter-regulation in diabetics is a selective form of autonomic neuropathy
- PMID: 589316
- PMCID: PMC1632815
- DOI: 10.1136/bmj.2.6101.1527
Defective blood glucose counter-regulation in diabetics is a selective form of autonomic neuropathy
Abstract
Administration of a low-dose insulin infusion to normal subjects results in a mild drop in blood glucose concentration (1.1 mmol/1 (20 mg/100 ml)) and the resetting of the basal glucose at the lower concentration. Clinical hypoglycaemia does not develop, and there is a significant release of glucagon, growth hormone, and cortisol. A similar infusion in insulin-requiring diabetics results in hypoglycaemia accompanied by a release of growth hormone and cortisol but no significant release of glucagon. Subsequently giving arginine to these patients results in a significant release of glucagon, indicating that the alpha cell is intact and can respond to local, direct stimulation. In one patient the defect in glucagon response to impending hypoglycaemia developed after two years' insulin treatment. This type of dissociated response' of the alpha cell has been reported in animals after denervation of the pancreas, and insulin-requiring diabetics may develop a selective form of autonomic neuropathy affecting the vagal control of glucagon release.
Similar articles
-
Lack of glucagon response to hypoglycemia in diabetic autonomic neuropathy.Diabetes. 1977 Mar;26(3):196-200. doi: 10.2337/diab.26.3.196. Diabetes. 1977. PMID: 838171
-
Glucagon response to hypoglycemia in diabetic neuropathy.Horm Metab Res Suppl. 1980;9:87-9. Horm Metab Res Suppl. 1980. PMID: 6929783
-
Somatostatin and counterregulatory hormone responses to hypoglycaemia in diabetics with and without autonomic neuropathy.Diabete Metab. 1985 Apr;11(2):81-6. Diabete Metab. 1985. PMID: 2861121
-
Failure of indomethacin to affect arginine-induced C-peptide and glucagon release in insulin-treated diabetics. Major role of residual B cell function in conditioning the magnitude of the blood glucose rise after intravenous arginine.Diabetologia. 1981 Oct;21(4):376-82. doi: 10.1007/BF00252685. Diabetologia. 1981. PMID: 7026333
-
Hypoglycaemia unawareness.Presse Med. 1994 Apr 2;23(13):623-7. Presse Med. 1994. PMID: 8029194 Review.
Cited by
-
Can beta-blockers be used in diabetic patients?Drugs. 1979 Mar;17(3):157-60. doi: 10.2165/00003495-197917030-00002. Drugs. 1979. PMID: 37063 No abstract available.
-
Counterregulation in type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis.Diabetologia. 1987 Dec;30(12):924-9. doi: 10.1007/BF00295875. Diabetologia. 1987. PMID: 3325324
-
Improved but not normalized glucose counter-regulation during glucagon infusion in Type 1 (insulin-dependent) diabetes.Diabetologia. 1984 May;26(5):337-42. doi: 10.1007/BF00266033. Diabetologia. 1984. PMID: 6376242
-
Nicotinic Signaling Stimulates Glucagon Secretion in Mouse and Human Pancreatic α-Cells.Diabetes. 2025 Jan 1;74(1):53-64. doi: 10.2337/db23-0809. Diabetes. 2025. PMID: 39475504 Free PMC article.
-
Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus.J Clin Invest. 1982 Feb;69(2):315-26. doi: 10.1172/jci110455. J Clin Invest. 1982. PMID: 6120181 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources